A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio ...

Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...